Nanogen set to acquire SynX Pharma

April 20, 2004 – Nanogen Inc. is expected to acquire SynX Pharma Inc. this week after shareholders, secured debt holders and an Ontario court approve the plan. San Diego-based Nanogen is set to acquire Toronto-based SynX on Wednesday in an all-stock transaction worth about $12 million. An Ontario Superior Court of Justice has approved the plan, but closing remains subject to other regulatory approvals and customary closing conditions, according to a news release.

SynX is a proteomics research and development company focused on preventing and managing diabetes and cardiovascular and central nervous system diseases. Nanogen develops microarrays and other molecular diagnostic products.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.